Pulmatrix, previously set to merge with Cullgen, has shifted its trajectory by announcing a merger with Eos SENOLYTIX, a biotech focusing on age-related muscle loss. This strategic move will pivot Pulmatrix’s operations under the Eos SENOLYTIX banner, with a new Nasdaq ticker symbol “EOSX.” The merger, which has been approved by both companies’ boards, is expected to finalize by mid-2026 and will see Pulmatrix shareholders owning approximately 6% of the new entity.

The merger emphasizes the growing interest in therapies targeting the biological mechanisms of aging, particularly through Eos SENOLYTIX’s lead candidate, PTC-2105. This compound aims to combat sarcopenia and enhance muscle mass and strength, potentially offering benefits beyond current GLP-1 therapies. With $19 million in private financing secured, the merged company is poised to advance its MitoXcel gerotherapeutic platform, which aims to address the root causes of aging-related diseases.

For professionals in the longevity field, this merger signals a promising avenue for developing innovative therapies that could significantly enhance healthspan and alter the landscape of age-related treatment strategies.

Source: fiercebiotech.com